Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 6/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.39 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047919 | 1.00 | MAPT (0.42) | MAPTTP53ENPP2SLC16A3SLC16A1 | |
| SCHEMBL1048828 | 0.92 | LMNA (0.41) | TP53ENPP2SLC16A3SLC16A1MCTS1 | |
| SCHEMBL4092629 | 0.92 | LMNA (0.41) | TP53ENPP2SLC16A3SLC16A1MCTS1 | |
| SCHEMBL1049263 | 0.91 | F2RL3 (0.43) | ENPP2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4109351 | 0.91 | F2RL3 (0.43) | ENPP2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4101180 | 0.90 | ENPP2 (0.42) | MAPTTP53ENPP2SLC16A3SLC16A1 | |
| SCHEMBL1049936 | 0.90 | ENPP2 (0.42) | MAPTTP53ENPP2SLC16A3SLC16A1 | |
| SCHEMBL1050774 | 0.89 | ENPP2 (0.39) | MAPTTP53ENPP2SLC16A3SLC16A1 | |
| SCHEMBL1050776 | 0.89 | ENPP2 (0.39) | MAPTTP53ENPP2SLC16A3SLC16A1 | |
| SCHEMBL4112646 | 0.88 | ENPP2 (0.41) | ENPP2SLC16A3SLC16A1MCTS1F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | MAPT 4627/4885TP53 4573/4885ENPP2 1075/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | MAPT 4829/4885TP53 343/4885ENPP2 3917/4885 |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | MAPT 4627/4885TP53 4573/4885ENPP2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.